XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
3 Months Ended 9 Months Ended 144 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS [Abstract]          
Research and development expenses, net $ 495,207 $ 469,836 $ 1,460,755 $ 1,423,364 $ 11,937,159
General and administrative expenses 232,189 216,190 786,259 664,738 3,800,901
Other income             (912)
Operating loss 727,396 686,026 2,247,014 2,088,102 15,737,148
Financing expenses (income), net (27,528) 14,530 373,046 [1] (15,135) 2,172,738
Loss for the period 699,868 700,556 2,620,060 2,072,967 17,909,886
Other comprehensive (income) loss:          
Foreign currency translation adjustment 37,308 8,069 56,108 (13,074) 65,033
Comprehensive loss for the period $ 737,176 $ 708,625 $ 2,676,168 $ 2,059,893 $ 17,974,919
Loss for the period attributable to common stockholders (Basic and Diluted) (Note 4) $ 0.16 $ 0.13 $ 0.52 $ 0.39   
Weighted average number of shares outstanding (Basic and Diluted) (Note 4) 5,299,927 5,295,543 5,341,551 5,295,543   
[1] Including issuance costs in an amount of US$ 390,928 allocated to the warrants with "down-round" protection. (See Note 3).